Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Artritis reumatoid ialah penyakit poliartritis kronik progresif yang menimbulkan deformasi, meliputi multisistem dan disertai morbiditas yang nyata. Obat-obatan imunosupresif telah digunakan untuk mengurangi/menghambat progresi penyakit. Penelitian ini diadakan untuk membandingkan keberhasilan azatioprin dan siklosporin pada penderita artritis reumatoid. Penelitian meliputi 100 penderita artritis reumatoid (sesuai kriteria American Rheumatism Association, 1987) yang dibagi atas dua kelompok: kelompok I mendapat azatioprin 1 mg/kg/h dan kelompok II mendapat siklosporin 2,5-3,0 mg/kg/h selama 16 minggu. Penilaian keberhasilan berdasarkan parameter klinis, biokimiawi dan radiologis. Semua penderita menunjukkan perbaikan nyata (nilai p < 0.001) pada semua parameter klinis, yaitu hilangnya nyeri, berkurangnya kekakuan pagi hari, sendi yang nyeri/membengkak dan waktu yang diperlukan untuk berjalan sejauh 50 kaki serta menguatnya kekuatan genggaman. Semua penderita menunjukkan penurunan LED (p < .001) tanpa perubahan apapun pada titer faktor reumatoid. Kedua obat menunjukkan keberhasilan yang sama (nilai p tidak bermakna) dalam hal perbaikan parameter klinis dan biokimiawi. Tetapi dengan siklosporin erosi tulang dan osteoporosis yukstaartikular lebih banyak berkurang. Sepuluh penderita menunjukkan nefrotoksisitas dengan siklosporin. Siklosporin lebih baik dari azatioprin dalam hal mengurangi derajat progresi kelainan sendi pada artritis reumatoid, tetapi insidens efek samping lebih tinggi, yang pada umumnya dapat diatasi. (Med J Indones 2002; 11: 153-7)

---

Rheumatoid Arthritis (RA) is a chronic progressive deforming polyarthritic disease involving multisystems and associated with considerable morbidity. Immunosuppressive drugs have been used to reduce/arrest the progression of the disease. The present study was undertaken to compare the efficacy of Azathioprine and cyclosporin in Rheumatoid Arthritis patients. Study consisted of 100 patients of Rheumatoid Arthritis (as per criteria of American Rheumatism Association, 1987) divided into two groups : group I received Azathioprine 1 mg/kg/d and group II received cyclosporin 2.5-3.0 mg/kg/d for 16 weeks. Assessment of efficacy was based on clinical, biochemical and radiological parameters. All patients showed marked improvemen (p value < 0.001) in all clinical parameters i.e. relief in pain, reduction in morning stiffness, painful/swollen joint along with walking time for 50 feet and increase in grip strength. All patients showed reduction (p < 0.001) in ESR without any change in rheumatoid factor titres. Both drugs showed equal efficacy (p value = NS) in improvement of clinical and biochemical parameters. But cyclosporin showed more reduction in bony erosions and juxtaarticular osteoporosis. Ten patients showed nephrotoxicity with cyclosporin. Cyclosporin has an edge over azathioprine in reducing the rate of progression of joint change in Rheumatoid Arthritis but is associated with increased incidence of side effects that are generally manageable. (Med J Indones 2002; 11: 153-7)

Abstrak :
ABSTRAK
Background Rheumatoid arhtirtis is a chronic autoimmune disease that mainly attacks joints. It may causes joint deformities which leads to lower quality of life of RA patients. RA is treated with metothrexate which inhibiting disease progression. MTX is known for its hepatotoxicity side effect, which is described by an elevation of aspartate aminotransferase and/or alanine aminotransferase beyond the upper normal limit. Factors that may enhance hepatotoxicity are gender, age, cummulative dose of MTX, and duration therapy of MTX. Prevalence of hepatotoxicity caused by MTX therapy in RA patients in Indonesia is still unknown. The objective of this research is to know the proportion of hepatotoxicity and its associations with the factors that may enhance hepatotoxicity caused by MTX therapy in RA patients in RSCM.Method Data about gender, age, cummulative dose and duration therapy of MTX are obtained from 115 RA patients medical records.Result Proportion of hepatotoxicity in RA patients treated with MTX in RSCM is 42.60 percent. Gender, age, cummulative dose and duration therapy of MTX do not significantly enhance hepatotoxicity p>0.05. Conclusion In conclusion gender, age, cummulative dose and duration therapy of MTX do not have association with hepatotoxicity in RA patients treated with MTX.

Abstrak :
ABSTRAK
Background Aim of this research is to assess the efficacy and safety of tocilizumab in combination with methotrexate in Indonesian patients with moderate to severe active rheumatoid arthritis who have an inadequate response to non biologic DMARDs.Methods This was a interventional, prospective, single arm, multicenter, study in Indonesian male or female patients aged > 18 years old, with a diagnosis of RA for > 6 months based on ACR 1987 revised criteria with moderate to severe disease activity DAS28 score > 3.2 after > 12 weeks of non biologic DMARDs treatment. The treatment consisted of tocilizumab, 8 mg/kg, intravenous, every 4 weeks for a total of 6 infusion in combination with oral MTX 10 until 25 mg every week. Efficacy was assessed based on the percentage of patients achieving low disease activity state DAS28 < 3.2, percentage of patients achieving reduction > 1.2 point of DAS28, percentage of patients achieving remission DAS28 < 2.6, and percentage of patients with ACR20, ACR50, and ACR70 responses. Descriptive statistics will be used for presentation of results.Results 100 percent patients reached low disease activity DAS28 < 3.2 at last study visit week 24 and clinically significant improvement reduction at least 1.2 units at every visit in DAS28, both for ITT or PP patients. Remission DAS28 < 2.6 was observed in 82.1 percent ITT patients and 93.1 percent PP patients on last study visit. ACR20, ACR50, and ACR70 were achieved in 20 percent, 34 percent, and 34 percent ITT patients, and 7 percent, 24 percent, and 62 percent PP patients on week 24. There were 3 out of 39 patients 7.69 percent with adverse events and serious adverse events that resulted in discontinuation of TCZ treatment, consisting of 1 patient with SAE of sepsis ec acquired community pneumonia, 1 patient with SAE of pneumonia tuberculosis, and 1 patient with AE of candidiasis. Most common adverse events were hepatic dysfunction 30.7 percent, hypercholesterolemia 23.1 percent, followed by arthralgia 20.5 percent Twelve percent of patients needed dose modification due to elevated liver enzyme elevated ALT/SGPT level. Conclusion Tocilizumab seems to be efficacious and likely to have good safety profile in non biologic DMARD nonresponsive RA patients of PICTURE INA study.

Abstrak :
Latar Belakang : Neuropati perifer merupakan manifestasi ekstraartikular pada Artritis Reumatoid AR yang sudah lama diketahui dan ditemukan pada sekitar 50-57,4 pasien AR dengan patogenesis yang belum jelas hingga saat ini. Nerve Growth Factor NGF, yang dilaporkan berhubungan dengan kejadian neuropati perifer pada pasien Diabetes Mellitus ditemukan dengan kadar yang lebih tinggi pada pasien AR dibandingkan orang normal. Berdasarkan hal tersebut, diperlukan penelitian yang bertujuan mengetahui hubungan antara kadar NGF dengan kejadian neuropati perifer pada pasien AR. Tujuan : Untuk mengetahui rata-rata kadar NGF darah dan ada tidaknya hubungan antara kadar NGF dengan kejadian Neuropati Perifer pada pasien AR. Metode : Penelitian potong lintang dengan metode consecutive sampling pada pasien AR rawat jalan di poli reumatologi Rumah Sakit Cipto Mangunkusumo dilakukan dalam kurun waktu Juli 2015-Maret 2016. Pemeriksaan laboratorium dan fisiologi yang dilakukan adalah NGF dan Elektromiografi-Kecepatan Hantar Saraf EMG-KHS. Subjek kemudian dikelompokkan menjadi 2 kelompok berdasarkan ada atau tidaknya neuropati perifer. Analisis bivariat kemudian dilakukan untuk melihat hubungan antara NGF dengan neuropati perifer diantara 2 kelompok. Data sekunder berupa usia, jenis kelamin, Laju Endap darah LED, C-Reactive Protein CRP, Disease Activity Score DAS 28 LED dan DAS 28 CRP didapat dari rekam medis sebagai data karakteristik dasar pasien. Hasil : Sebanyak 132 pasien diikutsertakan dalam penelitian ini dan didapatkan neuropati perifer sebanyak 45,5 60 orang selama Juli 2015-Maret 2016. Median kadar NGF pada pasien AR adalah 4,11 pg/mL 0,0-24,5 pg/mL. Median NGF pasien AR dengan neuropati perifer adalah 4,11 pg/mL 1,1-20,83 pg/mL, sementara median NGF pada pasien AR tanpa neuropati adalah 3,89 pg/mL 0,0-24,5 pg/mL. Jenis neuropati yang ditemukan pada pasien AR adalah polineuropati 29 subyek/21,97, mononeuropati multipleks 20 subyek/15,15 dan Carpal Tunnel Syndrome 15 subyek/11,36. Pada penelitian ini tidak didapatkan hubungan antara kadar NGF serum dengan kejadian neuropati perifer pada pasien AR p=0,716. Simpulan : Kadar NGF serum pasien AR didapatkan median sebesar 4 pg/mL dengan median NGF serum pada kelompok neuropati perifer 4,11 pg/mL dan kelompok tanpa neuropati 3,89 pg/mL. Tidak terdapat hubungan antara NGF serum dengan kejadian neuropati perifer pasien AR. ...... Background : Peripheral neuropathy is an extra articular manifestations in Rheumatoid Arthritis RA, which has been known and is found in approximately 50 to 57.4 of patients with RA with an unclear pathogenesis until now. In DM type 2 patients, Nerve Growth Factor NGF is associated with peripheral neuropathy. NGF level is also reported to be higher among RA patients than that of among healthy subjects. The correlation between NGF level and peripheral neuropathy among RA has not been concluded yet. Aim : To find out the mean levels of NGF blood serum and the relationship between the NGF serum levels and Peripheral Neuropathy among patients with RA. Methods : A cross sectional study using consecutive sampling method including patient of rheumatology clinic at Cipto Mangunkusumo hospital was performed between July 2015 to March 2016. The laboratory and physiology measurement incude NGF level and Electromyography Nerve Conduction Velocities EMG NCV were examined to the subjects. Patients were classified into 2 groups based on the diagnosis of Peripheral Neuropathy PN PN positive and PN negative. Bivariate analysis were done to investigate the relationship between NGF and PN among groups. Secondary data such as age, sex, Erythrocyte Sedimentation Rate ESR, CRP, Disease Activity Score DAS 28 ESR and CRP obtained from their medical record as a basic characteristic data of patients. Results : Among 132 subjects, PN was found in 60 subjects 45,5. The median level of NGF in RA patients was 4.11 pg mL 0.0 to 24.5 pg mL. The median NGF level of RA patients with peripheral neuropathy was 4.11 pg mL 1.1 to 20.83 pg mL, while the median of NGF level in RA patients without neuropathy was 3.89 pg mL 0.0 to 24.5 pg mL. Types of neuropathy among patients with AR were polyneuropathy 29 subjects 21.97, mononeuropathy multiplex 20 subjects 15.15 and Carpal Tunnel Syndrome 15 subjects 11.36. In this study we found no association between NGF serum level and peripheral neuropathy among patients with RA p 0.716. Conclusion : The median of NGF serum level among RA patients was 4 pg mL. The median of NGF serum level among peripheral neuropathy group was 4.11 pg mL while the median of NGF level in RA patients without neuropathy was 3.89 pg mL. There was no relationship between NGF serum level and peripheral neuropathy among patients with RA.

Abstrak :
Latar Belakang: Kehilangan massa tulang pada artritis reumatoid (AR) terjadi akibat ketidakseimbangan proses resorpsi dan formasi tulang. Tumor necrosis factor-α (TNF-a) adalah salah satu sitokin proinflamasi utama yang secara langsung dapat menyebabkan peningkatan resorpsi tulang, namun peranannya pada proses formasi tulang belum secara jelas diketahui. Aktivitas formasi tulang dapat dihambat oleh Dickkopf-1 (DKK-1) yang meningkat pada pasien AR. Penilaian turnover tulang dapat dilakukan dengan mengukur kadar C-terminal telopeptide (CTX) dan N-terminal propeptide (PINP) yang saat ini menjadi standar untuk penanda turnover tulang. Tujuan: Penelitian ini bertujuan untuk mendapatkan gambaran aktivitas turnover tulang pada pasien AR dengan melihat korelasi antara TNF-α dengan DKK-1 dan CTX untuk penilaian resorpsi tulang, dan korelasi antaran TNF-α dengan DKK-1 dan P1NP untuk penilaian formasi tulang. Metode: Penelitian ini merupakan studi potong lintang dengan 38 subjek artritis reumatoid perempuan premenopause. Pengambilan sampel dilakukan secara konsekutif di poliklinik reumatologi Rumah Sakit Cipto Mangunkusumo. Pemeriksaan TNF-α, DKK-1, CTX, dan P1NP dilakukan dengan metode ELISA. Hasil: Pada penelitian ini didapatkan median durasi menderita penyakit adalah 5 tahun. 60,5% pasien berada dalam kondisi remisi atau aktivitas penyakit rendah, 36,8% dalam kondisi aktivitas penyakit sedang, dan 2,6% pasien dalam kondisi aktivitas penyakit tinggi. Didapatkan median kadar TNF-a adalah 10.6 pg/mL, rerata kadar DKK-1 adalah 4027 pg/mL, rerata kadar CTX adalah 2,74 ng/mL, serta median nilai P1NP adalah 34 pg/mL. Kadar DKK-1 dan CTX dijumpai lebih tinggi sedangkan kadar P1NP lebih rendah jika dibandingkan dengan kadar pasien AR pada penelitian-penelitian sebelumnya. Penelitian ini menemukan korelasi positif lemah antara TNF-α dengan P1NP, sedangkan variabel lain tidak menunjukkan korelasi yang signifikan. Simpulan: Pada penelitian ini ditemukan korelasi positif lemah antara TNF-α dengan P1NP. Dijumpai kadar TNF-a yang rendah, DKK-1 yang tinggi, dan CTX yang tinggi dengan kadar P1NP yang rendah yang menunjukkan respon perbaikan tulang pada pasien AR tidak dapat mengimbangi tingginya aktivitas resorpsi tulang.

---

Background: Bone mass loss in rheumatoid arthritis (RA) is due to the imbalance of bone resorption and formation process.Tumor necrosis factor-α (TNF-a) is one of the main proinflammatory cytokines that can directly increase bone resorption, but its effect on bone formation is still uncertain. Bone formation could be inhibited by Dickkopf-1 (DKK-1) that is increased in RA patients. Bone turnover could be determined by assessing the level of C-terminal telopeptide (CTX) and N-terminal propeptide (PINP), both are standard measurement for bone turnover markers. Objective: This study aims to examine bone turnover in RA patients by analysing correlation between TNF-α with DKK-1 and CTX for assesment of bone resorption, and correlation between TNF-α with DKK-1 and P1NP for assesment of bone formation. Methods: This is a cross-sectional study with 38 subjects of RA premenopausal women. The subjects were collected with consecutive sampling technique in rheumatology outpatient clinic in Rumah Sakit Cipto Mangunkusumo, Jakarta. Measurement of serum TNF-α, DKK-1, CTX, and P1NP levels were done using ELISA technique. Results: The median duration of RA in this study is 5 years. 60,5% of the patients were in remission or low activity disease, 36,8% were in moderate activity disease, and 2,6% were in high activity disease. The median value of TNF-a was 10.6 pg/mL, mean value of DKK-1 was 4027 pg/mL, mean value of CTX was 2,74 ng/mL, and mean value of P1NP was 34 pg/mL. DKK-1 and CTX levels were increased while P1NP level was lower compared to the RA patients in previous studies. This study found weak positive correlation between TNF-α and P1NP, while the other variables showed no significant correlation. Conclusions: This study demonstrated weak positive correlation between TNF-α and P1NP. We found low level of TNF-α, high level of DKK-1, and high level of CTX with low level of P1NP that indicate that the bone repair response could not keep up to the high bone resorption activity in RA patients.

Abstrak :
Pendahuluan: Andrografolida, konstituen aktif utama diisolasi dari Andrographis paniculata yang digunakan untuk terapi artritis reumatoid. Namun, senyawa ini memiliki bioavailabilitas oral yang rendah. Masalah ini dapat diatasi dengan memformulasikan andrografolida dalam etosom melalui pemberian transdermal. Tujuan: Penelitian ini bertujuan untuk mengetahui profil farmakokinetik, bioavailabilitas relatif, dan efektivitas sediaan transdermal etosom andrografolida pada hewan model artritis reumatoid. Metode: Metode hidrasi lapis tipis digunakan untuk memformulasikan etosom andrografolida. Karakterisasi etosom meliputi ukuran partikel, indeks polidispersitas, potensial zeta, dan efisiensi penjerapan. Pada uji farmakokinetik, digunakan GE, GNE dan SO dosis 50 mg/kgbb kemudian sampel plasma diambil dari sinus retro-orbital dengan 10 titik pengambilan dalam 24 jam. Parameter farmakokinetik dianalisis dengan KCKT fase terbalik. Pada uji aktivitas antiartritis, GE dosis 25, 50, dan 100 mg/kg diberikan secara transdermal pada tikus uji yang diinduksi CFA 0,1 mL. Selama fase induksi dan setelah pemberian obat, manifestasi klinis artritis dipantau menyeluruh. Hasil: Hasil penelitian didapatkan etosom dengan ukuran partikel 76,35±0,74 nm, zeta potensial -40,17±1,03 mV dan efisiensi penjerapan 97,87±0,23%. Studi farmakokinetik menghasilkan Cmax pada GE, GNE, dan SO berturut-turut adalah 53,07±4,73; 27,34±1,48; dan 11,72±0,74 μg/mL, AUC0-∞ masing-masing 152,10±16,53; 77,15±12,28; dan 23,20± 3,46 μg.jam/mL. Tmax rute transdermal dicapai jam ke-6 sementara rute oral jam ke-2 setelah pemberian sediaan. Hasil uji aktivitas antiartritis mengungkapkan, GE 50 dan 100 mg/kgbb menunjukkan persentase penghambatan edema hampir serupa dengan metotreksat 0,135 mg, subkutan. Kesimpulan: Hasil penelitian disimpulkan bahwa GE 50 mg/kgbb menghasilkan peningkatan Cmax, Tmax dan AUC0-∞. Bioavailabilitas relatif dicapai sebesar 655,60% pada rute transdermal dibandingkan dengan rute oral. Hasil uji aktivitas antiartritis, GE 50 mg/kg secara efektif mengurangi volume edema, diameter kaki, dan skor artritis tikus model yang diinduksi CFA. ......Intoduction: The main active constituent isolated from Andrographis paniculata, andrographolide, is used to treat rheumatoid arthritis. This compound, however, has a low oral bioavailability. This issue can be solved by incorporating andrographolide into ethosomes for transdermal administration. Aim: This study was designed to determine the pharmacokinetic profile, relative bioavailability, and efficacy of andrographolide ethosomal transdermal preparations in animal models of rheumatoid arthritis. Method: Andrographolide was prepared into ethosomal dosage forms before being characterized in terms of particle size, polydispersity index, zeta potential, and entrapment efficiency. In the pharmacokinetic test, plasma sampels were collected from the retro-orbital sinus at 10 collection points over the course of 24 hours using GE, GNE, and SO at a dose of 50 mg/kg each. Reverse-phase HPLC was used to assess pharmacokinetic parameters. In the anti-arthritic activity test, GE doses of 25, 50, and 100 mg/kg were administered transdermally to rats induced by 0.1 mL CFA. The clinical manifestations of arthritis are closely monitored during the induction phase and after drug administration. Result: According to the results, the ethosomes with a particle size of 76.35±0.74 nm, a zeta potential of -40.17±1.03 mV, and an entrapment efficiency of 97.87±0.23%. Pharmacokinetic studies revealed that the Cmax in GE, GNE, and SO was 53.07±4.73, 27.34±1.48, and 11.72±0.74 μg/mL, and the AUC0-∞ was 152,10±16,53; 77,15±12,28; and 23,20± 3,46 μg.jam/mL, respectively. The transdermal route had a Tmax of 6 hours, while the oral route had a Tmax of 2 hours after administration of the preparation. GE 50 and 100 mg/kg inhibited edema with nearly the same percentage as methotrexate 0.135 mg subcutaneously, according to the anti-arthritis activity test. Conclusion: The researchers concluded that GE 50 mg/kg caused an increase in Cmax, Tmax, and AUC0-∞. The transdermal route has a relative bioavailability of 655.60% compared to the oral route. The anti-arthritis activity study showed that GE 50 mg/kg effectively reduced edema volume, paw diameter, and arthritis scores in CFA-induced rat models.

Abstrak :
Pendahuluan. Artritis Reumatoid (AR) adalah suatu penyakit autoimun yang bersifat sistemik dan kronik yang manifestasi utamanya melibatkan persendian. Tatalaksana AR membutuhkan terapi medikamentosa dan pendekatan gaya hidup. Salah satu tatalaksana AR adalah medikamentosa dengan metotreksat (MTX). Ada banyak faktor yang memengaruhi keberhasilan terapi AR namun di Indonesia belum ditemukan studi yang meneliti obesitas terhadap keberhasilan terapi MTX pada pasien AR di Indonesia. Peneliti ingin mengetahui pengaruh obesitas terhadap ketidakberhasilan terapi MTX monoterapi pada pasien dengan AR. Metode. Studi kohort retrospektif menggunakan data rekam medis Poli Reumatologi Penyakit Dalam, Rumah Sakit Cipto Mangunkusumo (RSCM) pada kurun waktu Maret 2017-Desember 2021. Dilakukan analisis deskriptif untuk melihat karakteristik sampel berdasarkan tiap variabel dan analisis regresi Cox yang dimodifikasi untuk melihat hubungan antara obesitas terhadap ketidakberhasilan terapi MTX. Hasil. Dari 72 subyek, proporsi ketidakberhasilan terapi pada pasien obesitas adalah 57.1% (20/35), sementara pada pasien yang tidak obesitas adalah 37.8% (14/37). Risiko ketidakberhasilan terapi MTX pada pasien dengan obesitas adalah 1,45 kali dibandingkan pasien yang tidak obesitas (RR 1,45; 95% CI 0,76-2,78). Faktor jumlah sendi yang terlibat, faktor RF, faktor C-reactive protein, usia, laju endap darah, jenis kelamin, dan onset awal sakit bukan merupakan faktor perancu pada studi ini. Kesimpulan. Pada studi ini, pasien AR dengan obesitas meningkatkan risiko untuk mengalami ketidakberhasilan terapi MTX dibandingkan pasien AR tanpa obesitas, namun diperlukan studi lebih lanjut menggunakan sampel yang lebih besar untuk meningkatkan kekuatan statistik. ......Introduction. Rheumatoid arthritis (RA)) is a systemic and chronic autoimmune disease which main manifestations involve the joints. AR management requires medical therapy and a lifestyle approach. One of the AR treatments is medication with methotrexate (MTX). There are many factors that influence the success of AR therapy but in Indonesia there has not been found a study that examines obesity on the success of MTX therapy in AR patients in Indonesia. Researchers wanted to know the effect of obesity on the failure of MTX monotherapy in patients with AR Methods. A retrospective cohort study using medical records from the Rheumatology Internal Medicine Polyclinic, Cipto Mangunkusumo Hospital (RSCM) from March 2017 to December 2021. A descriptive analysis was performed to see the sample characteristics based on each variable and a modified Cox regression analysis to see the relationship between obesity and failure of MTX therapy. Results. Of the 72 subjects, the proportion of treatment failure in obese patients was 57.1% (20/35), while in patients who were not obese it was 37.8% (14/37). The risk of MTX treatment failure in obese subjects was 1.45 times that of non-obese patients (RR 1.45; 95% CI 0.76-2.78). Number of joints involved, RF factor, C-reactive protein factor, age, erythrocyte sedimentation rate, gender, and early onset of illness were not confounding factors in this study. Conclusion. In this study, RA patients with obesity have an increased risk of MTX treatment failure MTX compared to RA patients without obesity, but further studies using larger samples are needed to increase statistical power.

Abstrak :
Latar Belakang Artritis reumatoid merupakan penyakit reumatik yang sering menyebabkan gangguan fungsional dan penurunan kualitas hidup. Faktor-faktor yang berbeda telah dilaporkan mempengaruhi kualitas hidup pasien AR. Penelitian ini bertujuan mengetahui rerata kualitas hidup pasien AR dan faktor-faktor yang berperan dalam kualitas hidup pasien AR. Metode Penelitian Sebanyak 152 subjek direkrut dari Poliklinik Reumatologi RSUPN Dr. Cipto Mangunkusumo Jakarta. Data mengenai sosiodemografi, kondisi klinis dan laboratorium yang berkaitan dengan aktivitas penyakit, status fungsional, masalah psikologis, dan jumlah komorbiditas diambil dalam penelitian ini. Kualitas hidup diukur menggunakan kuesioner EuroQol five demensional (EQ-5D) and EQ global health visual analogue (VAS). Analisis dilakukan secara univariat, bivariat, dan multivariat. Hasil Penelitian Sebayak 90,8% perempuan dengan rerata usia 49,41 ± 12,31 tahun dengan tingkat pendidikan menengah serta tidak bekerja. Mayoritas subjek memiliki derajat aktivitas penyakit sedang (median 3.26 (1,03 – 6,89) dan status fungsional mandiri. Median durasi penyakit penyakit 3 (0 – 34) tahun. Gangguan psikologis seperti ansietas (11,2%) dan depresi (20,4%) juga ditemukan. Median nilai indeks 0,84 (0,170 – 1,000) dan median nilai EQ VAS 70 40 – 100). Faktor-faktor yang secara independen berperan dalam nilai indeks adalah disabilitas fungsional, aktivitas penyakit, dan depresi, sedangkan untuk EQ VAS disabilitas fungsional, aktivitas penyakit, depresi, ansietas dan komorbiditas untuk EQ VAS. Kesimpulan Disabilitas fungsional, aktivitas penyakit, gangguan psikologis dan jumlah komorbiditas memiliki pengaruh negatif terhadap kualitas hidup pasien AR. Sehingga evaluasi terhadap faktor-faktor tersebut harus dipertimbangkan dalam standar pelayanan pasien AR dan tatalaksana yang sesuai harus dioptimalkan. ......Background. Rheumatoid arthritis (RA) is a rheumatic disease that often causes functional disorders and decreased health related quality of life (HRQoL). Different factors have been reported affecting HRQoL of RA patients. This study aims to evaluate the HRQoL and related factors in patients with RA. Methods. One hundred and fifty-two patients from Reumatology polyclinic at RSUPN Dr. Cipto Mangunkusumo Jakarta were enrolled. Data about sosiodemographic, clinical and laboratory data related to disease activity, functional status, psyological problem, and number of comorbidities were collected. HRQoL was assessed using the Indonesian EuroQol five demensional questionnaire (EQ-5D) and EQ global health visual analogue (VAS). Univariate analysis, bivariate and multivariate analysis were employed to identify factors related to HRQoL. Results. Ninety percent were female with a mean age ± Sof 49.41 ± 12.31 years with a secondary education level and unemployed. Majority of subjects had moderate disease activity (median 3.26 (1.03 – 6.89) and independent functional status. Median duration of illness was 3 (0 – 34) years. Psychological disorders such as anxiety (11.2%) and depression (20 .4%) were also found, the median index value 0.84 (0.170 – 1,000) and the median EQ VAS 70 40 – 100). The factors that independently played a role in the index score were functional disability, disease activity, and depression, while for the EQ VAS were functional disability, disease activity, depression, anxiety, and number of comorbidities. Conclusion. Functional disability, disease activity, psychological disorders and the number of comorbidities have a negative influence on the HRQoL of RA patients. So, the evaluation of these factors must be considered in the standard of care for RA patients and the appropriate management must be optimized